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Since its initial discovery in the 1940s, factor V has long been viewed as an important procoagulant
protein in the coagulation cascade. However, in the later part of the 20th century, two different scientists
proposed novel anticoagulant roles for factor V. Philip Majerus proposed the ﬁrst anticoagulant function
for factor V in 1983, yet ultimately it was not widely accepted by the broader scientiﬁc community. In
contrast, Björn Dahlbäck proposed a different anticoagulant role for factor V in 1994. While this role was
initially contested, it was ultimately accepted and integrated into the scientiﬁc framework. In this paper, I
present a detailed historical account of these two anticoagulant discoveries and propose three key
reasons why Dahlbäck’s anticoagulant role for factor V was accepted whereas Majerus’ proposed role was
largely overlooked. Perhaps most importantly, Dahlbäck’s proposed anticoagulant role was of great
clinical interest because the discovery involved the study of an important subset of patients with
thrombophilia. Soon after Dahlbäck’s 1994 work, this patient population was shown to possess the factor
V Leiden mutation. Also key in the ultimate acceptance of the second proposed anticoagulant role was
the persistence of the scientist who made the discovery and the interest in and ability of others to
replicate and reinforce this work. This analysis of two different yet similar discoveries sheds light on
factors that play an important role in how new discoveries are incorporated into the existing scientiﬁc
framework.
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).full journal title Studies in History and Philosophy of Biological and Biomedical Sciences1. Introduction commit experimenters to completely changing the direction of
their research activities.” (Rheinberger, 1997) (p134). While theFactor V is a key component of the coagulation cascade, and it
has long been established as an important protein in clot formation.
However, ﬁrst in 1983 and then again in 1994, two different anti-
coagulant (clot inhibiting) roles for factor V were proposed. The
ﬁrst proposed anticoagulant role was acknowledged brieﬂy by
biochemists but then it was largely forgotten, whereas the second
proposed anticoagulant role was rejected initially but then even-
tually it was largely accepted (Fig. 1). In this paper, I explore these
two related factor V cases, each inwhich an “unprecedented event”
occurred. In Rheinberger’s words, “Unprecedented events are about
things and concatenations not sought for. They come as a surprise
but nevertheless do not just so happen. . And yet they maytd. This is an open access article ufactors and conditions that lead to unprecedented events are crit-
ical in the process of scientiﬁc understanding, perhaps equally
important is what happens after novel discoveries are made. Given
that the unprecedented event from 1994 did lead to a change in the
path of future research and the 1983 discovery did not, these two
cases serve as a means to explore the issue of how a relevant sci-
entiﬁc community responds to reports of novelty and achieves
consensus about whether and to what extent new ﬁndings should
be incorporated into the existing framework.
There are many examples of unexpected ﬁndings being rejected
or overlooked by the scientiﬁc community. When Francois Jacob
ﬁrst reported on his discovery of messenger RNA (which he termed
component X at the time), scientists did not readily accept his
ﬁndings. In fact, “No one reacted. No one batted an eyelash. No
one asked a question. Jim [Watson] continued to read hisnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. The relative incorporation of the proposed factor V anticoagulant roles into the
existing scientiﬁc framework over time. The 1983 proposal refers to Majerus’ proposed
anticoagulant role for factor V. The 1994 proposal refers to Dahlback’s proposed
anticoagulant role for factor V. Image is not to scale.
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put forth by scholars to explain why some discoveries are over-
looked whereas others are more readily accepted by the scientiﬁc
community. One argument is that discoveries are more likely to be
overlooked if they do not clearly ﬁt in with the existing scientiﬁc
knowledge (Brannigan, 1981; Hook, 2002b; Stent, 1972). Other
factors proposed to inﬂuence the reception of a discovery have
included the status of the scientist, the relevance of the ﬁnding, to
what extent the discovery is noticed, and whether the ﬁnding can
be replicated (Brannigan, 1981; Gillies, 2005; Hook, 2002b; Latour
& Woolgar, 1986).2 To further explore potential determinants of
how discoveries are received, the two factor V anticoagulant cases
presented in this paper offer an important comparison because two
similar discoveries followed two very different trajectories.
By looking at these two cases of proposed anticoagulant roles for
factor V in parallel,3 I hope to demonstrate the key factors that
determined why only one of the two proposed anticoagulant roles
for factor V became a matter of concern4 (Latour, 2004, 2005).
Perhaps most signiﬁcant is the perceived clinical relevance of the
factor V anticoagulant function discovered in 1994. In fact, the 1994
discovery was based on analysis of a population of patients with
thrombophilia who would not long after be shown to possess the
factor V Leiden mutation. In addition, Björn Dahlbäck, who made
the 1994 discovery, was extremely persistent in the promotion of
his hypothesis. Dahlbäck’s persistence, coupled with the clinical
signiﬁcance of his discovery, resulted in replication and extension
of the work and ultimate widespread acceptance of the 1994 factor
V anticoagulant role. To fully appreciate these cases, I begin with a
scientiﬁc overview of factor V.1 Quoted from Jacob (1988), p311.
2 The reasons that potentially inﬂuence the acceptance of scientiﬁc ﬁndings are
expanded upon in the discussion section.
3 The historical analysis relies on published work and one interview. Björn
Dahlbäck, the discoverer of the second proposed anticoagulant role of factor V, was
interviewed by ML in 2013. The interview protocol was approved by the Wellesley
College IRB. Philip Majerus and colleagues did not respond to interview requests.
One of Majerus’ coauthors on the 1983 article wrote ML, “I am not the best person
for you to be talking to. Highly suggest Björn Dahlbäck.” Björn Dahlbäck and Philip
Majerus’ papers are in their possession.
4 Latour proposes that scientiﬁc information becomes a “matter of concern”
when a ﬁnding becomes relevant. The second proposed anticoagulant role for
factor V became relevant, or a matter of concern, due in large part to the clinical
signiﬁcance of the ﬁnding (Latour, 2004; Latour, 2005).2. Procoagulant factor V
In 1943, a young woman named Mary came to a hospital in
Norway because of a bleeding episode (Stormorken, 2003). Mary
had been healthy for the ﬁrst few years of her life, but she had
suffered a severe bleeding episode at the age of three that left her
blind, initially in both eyes. She had many bleeding episodes in the
subsequent years, but menstrual bleeding proved to be the most
problematic for Mary. It was for this reason that she came to the
hospital at the age of 29. Paul Owren, an assistant professor at the
hospital, was responsible for her care, and after laborious effort, it
was hewho discovered that she had a deﬁciency in a clotting factor.
At that time, the theory of blood coagulation included just four
clotting factors, so Owren named Mary’s missing protein factor V,
setting the precedent for the use of roman numerals in naming the
blood coagulation factors (Giangrande, 2003; Stormorken, 2003).
He published his work in Norway in 1944, but his results were not
widely known until after the war, when he was able to publish in
The Lancet (Owren, 1947).
Owren’s ﬁndings “spurred an unprecedented activity in the
ﬁeld”(Stormorken, 2003), and factor V has since been known to
play a key role as a procoagulant protein in the coagulation cascade.
By the early 1980s, there was a consensus model for how the
clotting cascade worked. The activated form of factor V, termed
factor Va, was known to play an important role in the coagulation
cascade because it serves as a cofactor in the conversion of pro-
thrombin to thrombin. The enzyme thrombin cleaves ﬁbrinogen
into ﬁbrin, which binds to and crosslinks platelets, resulting in a
platelet plug and clot formation. Patients who are missing factor V
have serious bleeding disorders because they are unable to
generate factor Va. To properly regulate the coagulation cascade so
that clotting doesn’t continue out of control, factor Va can be
inhibited by activated protein C (APC), thereby shutting down the
cascade (Fig. 2).Fig. 2. Summary of some key components of the coagulation cascade as of the early
1980s. Factor V is converted to the procoagulant factor Va. Factor Va is instrumental in
the conversion of prothrombin to thrombin. A cascade continues in which ﬁbrinogen is
converted to ﬁbrin, free platelets are converted to a platelet plug, and clot formation
occurs. Activated protein C serves as an anticoagulant protein by inactivating factor Va.
Some details are omitted for clarity.
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Surprisingly, given how well established factor V/Va was as a
procoagulant, two different anticoagulant functions for factor V
were proposed in the later part of the twentieth century (Fig. 3).
The ﬁrst study to suggest this apparently contradictory role was
published in 1983, in which scientists postulated that factor Va was
a cofactor in the thrombin-mediated activation of protein C to APC.
In other words, factor Va was able to stimulate production of the
anticoagulant protein APC. Because it was already established that
APC shuts down the coagulation cascade by inactivating factor Va,
as well as another procoagulant protein, factor VIIIa, these re-
searchers were proposing that factor Va somehowhad both the role
of driving coagulation as well as facilitating the process whereby
coagulation would be shut down. A decade later, in 1994, a new set
of researchers published ﬁndings suggesting that factor V (the
inactive precursor to the procoagulant factor Va) was a direct
cofactor in the anticoagulant function of APC. Once again, it
appeared that a procoagulant protein also possessed an anticoag-
ulant function.
In both cases, the proposal of these unexpected functions for
factor V and factor Va was difﬁcult for biochemists to accept, and
the 1983 research became so forgotten that the 1994 publication
failed to reference it. In fact, the scientists who authored the 1994
publication went so far as to claim that their group was the ﬁrst to
propose an anticoagulant role for factor V. The research and ideas
triggered by the 1994 publication gained eventual traction and
acceptance by clinical biochemists whereas the 1983 publication
was largely ignored.4. Philip Majerus and the ﬁrst proposed anticoagulant role
for factor V
After having trained as an undergraduate at Notre Dame Uni-
versity and a medical student at Washington University, Philip
Majerus completed his residency at Massachusetts General Hos-
pital in 1963 (Majerus, 2011; Nemeh, Kalte, & Schusterbauer, 2005).
Faced with the choice of serving as a physician in Vietnam or
beginning a research career, he chose to take a position at the
National Institutes of Health. At that time, Earl Stadtman was the
head of the laboratory of biochemistry at the National HeartFig. 3. Summary of the proposed anticoagulant roles of factor V/Va. Factor V is con-
verted by thrombin and factor Xa to the active, procoagulant factor Va. Protein C is
converted by thrombin and thrombomodulin to activated protein C. APC serves an
anticoagulant function by cleaving and inactivating factor Va. The two anticoagulant
roles proposed for factor V/Va are indicated by dashed lines and the date of the pro-
posed anticoagulant role is shown. In 1983, factor Va was proposed to be a cofactor in
the thrombin-mediated activation of protein C to APC. In 1994, factor V was proposed
to be a cofactor in the APC-mediated cleavage of factor Va and another procoagulant
protein, factor VIIIa (not shown).Institute and P. Roy Vagelos was one of a number of independent
investigators working under Earl Stadtman (Marks, 2011). Majerus
chose to work directly with Roy Vagelos, who would become his
long-term mentor and friend. Majerus began research in the
Vagelos lab on fatty acid biosynthesis, and he published his ﬁrst
paper within a year of starting in the laboratory (Majerus, Alberts, &
Vagelos, 1964). In collaborationwith AlfredW. Alberts and Vagelos,
Majerus published a series of papers over just a few years
describing the complete fatty acid synthesis pathway (Alberts,
Majerus, Talamo, & Vagelos, 1964; Majerus, Alberts, & Vagelos,
1965a, 1965b).
In 1966, Majerus accepted a faculty position running his own lab
at the University ofWashington in the hematology division. Despite
his success with studying fatty acid synthesis and acyl carrier
protein, he soon realized that he would need to shift to a more
clinically-focused research program in order to maintain his posi-
tion (Majerus, 1967, 1968; Majerus, Jacobs, Smith, & Morris, 1968).
With his friend and colleague Stuart Kornﬁeld, he decided to learn
more about hematology and he soon switched his research focus to
that ﬁeld. He studied a variety of topics over the next several years
and published widely in both biochemical and clinical journals
(Harter et al., 1979; Roth & Majerus, 1975; Roth, Stanford, Jacobs, &
Majerus, 1977).
Beginning in the late 1970s, Majerus began publishing work
on factor V. He initially studied patients with factor V deﬁciency
and demonstrated that their platelets were impaired in the
ability to bind another coagulation factor, factor Xa. Published
work had already demonstrated the importance of factor V in
enhancing the factor Xa-mediated conversion of prothrombin to
thrombin, and Majerus was able to demonstrate that factor Va
functions by enhancing the binding of factor Xa to platelets
(Kane, Lindhout, Jackson, & Majerus, 1980; Miletich, Jackson, &
Majerus, 1978; Miletich, Majerus, & Majerus, 1978). In 1981,
Majerus and Kane puriﬁed human factor V and described the
biochemical characterization of this protein5 (Kane & Majerus,
1981).
After studying the procoagulant function of factor V for several
years, Majerus’ lab came across an interesting and novel ﬁnding. In
a publication in the Proceedings of the National Academy of Sciences
in 1983, Hatem Salem, Majerus and colleagues described the ﬁrst
anticoagulant function for factor Va (Salem, Broze, Miletich, &
Majerus, 1983a). At the time of their publication, thrombin was
already known to activate protein C. However, the thrombin-
mediated activation of protein C was rather slow. Therefore, the
researchers were interested in trying to identify a serum compo-
nent that was capable of enhancing the activation of protein C. To
ﬁnd the serum factor, they began with serum in which the
endogenous factor Va had been inactivated. They then added factor
Va to this modiﬁed serum and measured protein C activation. Since
activated protein C, or Ca as it was called at the time, was known to
inactivate factor Va, theymeasured factor Va inactivation as a proxy
for protein C activation. Interestingly, they observed a 10e
20 min lag between the time they added factor Va and the time it
was inactivated. They concluded that the protein C must be acti-
vated during that initial lag period, and that “factor Va might
participate in protein C activation.”(Salem et al., 1983a) To conﬁrm
their suspicions, they switched to puriﬁed components to test the
role of factor Va as a cofactor in the activation of protein C. In a test5 Interestingly, Kane and Majerus became aware of Björn Dahlbäck’s 1980 char-
acterization and puriﬁcation of factor V “by a method different from that reported”
in their manuscript. Kane and Majerus state, “The preparation was essentially
identical with ours although it was obtained in a much lower yield.” (Kane &
Majerus, 1981).
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control, they added just puriﬁed protein C and thrombin. As a proxy
for protein C activation, they again measured the inactivation of
factor Va over time. Using this assay, they demonstrated that factor
Va is a cofactor in the thrombin-mediated cleavage of protein C to
protein Ca (later called activated protein C, or APC). This activity is
signiﬁcant because activated protein C is able to cleave and inac-
tivate not just the procoagulant factor Va, but an additional pro-
coagulant termed factor VIIIa as well. In their cell-free system of
puriﬁed protein components, the presence of factor Va resulted in a
50-fold increase in the production of protein Ca by thrombin, a
strong anticoagulant response from a protein that previously had
been a centerpiece of the coagulation cascade. One might have
expected a signiﬁcant scientiﬁc interest in this ﬁnding because of
the accepted procoagulant role of factor V at the time of Majerus’
study, but the work was not widely referred to.
One reason for the minimal response to Majerus’ publication
was that the anticoagulant factor Va had some competition for the
limelight. In fact, shortly beforeMajerus published his novel ﬁnding
regarding the anticoagulant role for factor Va, Charles Esmon from
the Oklahoma Medical Research Foundation and colleagues had
discovered a new molecule, which they termed thrombomodulin,
that also served as a cofactor for the thrombin-mediated activation
of protein C to protein Ca (Esmon, Owen, & Esmon, 1982). Majerus
and colleagues referred to thrombomodulin in their paper and
stated, “The relationship, if any between factor Va and thrombo-
modulin remains to be elucidated. Factor Va is at least as potent as
thrombomodulin.”(Salem et al., 1983a) In a follow-up paper in the
same year, Majerus and colleagues demonstrated that the light
chain of factor Va is responsible for its ability to serve as a cofactor
in the thrombin-mediated activation of protein C to protein Ca
(Salem, Broze, Miletich, & Majerus, 1983b). They also stressed that
they had considered whether factor Va and thrombomodulin were
the same molecule, but that they ruled out this possibility due to
different functional abilities of the two molecules. In fact, they
provided three distinct functional lines of evidence to support their
claim that thrombomodulin and the factor V light chain were
different molecules. While maintaining that both proteins were
signiﬁcant and might even work in synergy, Majerus and his col-
leagues did state that thrombomodulin seemed to work better as a
cofactor than factor Va. In fact, Majerus and Salem collaborated
with Naomi Esmon and Charles Esmon to compare the ability of
thrombomodulin and the light chain of factor Va to serve as co-
factors in the thrombin-mediated activation of protein C. In work
published in the Journal of Clinical Investigation in 1984, they
demonstrated that thrombomodulin was 20 times more efﬁcient
than the factor Va light chain at serving as a cofactor for the
thrombin-mediated activation of protein C (Salem, Esmon, Esmon,
& Majerus, 1984). It seems, then, that one potential reason Majerus’
discovery of the factor Va anticoagulant function didn’t resonate
with the broader scientiﬁc community was that it was over-
shadowed by a newly discovered and more potent anticoagulant
protein.
Recognizing the paradoxof a protein having both a procoagulant
and an anticoagulant role, Majerus and colleagues worked dili-
gently over the next several years to elucidate this seeming
incongruence and to explain how the regulation of coagulation
worked. In the same collaboration with the Esmons, Salem and
Majerus showed that the factor Va light chain could inhibit the
ability of thrombomodulin to serve as a cofactor in the activation of
protein C. In contrast, thrombomodulin was not able to inhibit the
ability of factor Va to serve as a cofactor for protein Ca production.
The authors hypothesized (but did not formally test) that this dif-
ferential inhibition could be an important mechanism of regulation
of the protein C pathway.Although the physiological signiﬁcance of these interactions is
not immediately apparent, it is possible to postulate a control
mechanism. Low levels of FVa-LC [the light chain of factor Va] or
intact factor Va stimulate thrombomodulin activity on endo-
thelial cells., thereby promoting protein Ca generation. Thus,
the protein Ca formed may then hydrolyze the Factor Va heavy
chain leaving the FVa-LC behind. As the FVa-LC accumulates,
inhibition of thrombomodulin activity could then result, pre-
venting continued protein C activation once sufﬁcient Factor Va
has been inactivated.(Salem et al., 1984)
To summarize, they surmised that the ability of factor Va to inhibit
thrombomodulin served as a way to regulate the amount of protein
C that was activated. When factor Va levels dropped due to inac-
tivation by protein Ca, thrombomodulin would be inhibited by the
factor Va light chain and production of protein Ca (which would no
longer be needed) would drop. In a subsequent publication, Maje-
rus and colleagues went on to state: “In this way factor Va could
both limit coagulation by stimulating protein C activation and also
prevent the excessive generation of activated protein C by blocking
its further formation once the need to limit coagulation has ended.
We plan further experiments to evaluate the validity of this
hypothesis”(Maruyama, Salem, & Majerus, 1984) In this summa-
tion, it seemed that Majerus and colleagues had found an elegant
explanation for the apparently opposing roles for factor Va, and
they proposed future experiments to test their hypothesis. Yet, this
was the last primary research paper to come out of the Majerus lab
on the subject (only a review article from the Esmon and Majerus
labs followed) (Salem, Esmon, Esmon, & Majerus, 1986).
Independent labs did not replicate or reinforce this work and
this new characteristic of factor V was not incorporated into the
larger framework. Rheinberger argues that “the appearance of a
new trait related to the epistemic object under scrutiny need not
eliminate earlier traits. They may, however, decrease in promi-
nence, be reduced to marginality, dissolve into background noise,
or simply be forgotten.” (Rheinberger, 1997) (page 88e89). How-
ever, in the case of the anticoagulant function of factor Va that was
discovered in 1983, the “new trait,” or anticoagulant function, is the
one that is forgotten. While the details of protein synthesis, as
Rheinberger illustrates, were not well established in the early
1950s, the coagulant function of factor V was well established by
the early 1980s. There are perhaps many reasons why this new
anticoagulant trait did not come to the forefront. It may also be
possible that new traits typically only come to the forefront if the
old traits are not well established. As discussed earlier, thrombo-
modulin may have overshadowed factor Va as a cofactor for the
activation of protein C. Additionally, the speciﬁc role of factor Va as
both a procoagulant and anticoagulant protein may have been
viewed as counter-intuitive and therefore difﬁcult to accept by
scientists at the time. Furthermore, since there was no clear clinical
signiﬁcance to this ﬁnding, it may not have captured the interest of
other scientists.
Given the string of successful investigations into the anticoag-
ulant role of factor Va, why did Majerus’ research on the topic come
to such a sudden halt? In this instance, it could be that Majerus had
more than one line of research going on in his laboratory at the time
and his interests shifted away from the factor Va anticoagulant
work because of greater interest in a different topic. In the mid-
1980s, Majerus was in the midst of seminal research on phos-
phoinositides. In fact, his work on “the thrombin-induced hydro-
lysis of phosphatidylinositol in human platelets,” which was
presented in three Journal of Biological Chemistry papers spanning
1982e1985, was recently honored in the journal (Kresge, Simoni, &
Hill, 2008). Upon stimulation, phosphatidylinositol is cleaved to
produce soluble messenger molecules. These phosphatidylinositol-
6 Interestingly, Dahlbäck coauthored an article about coagulation (but not factor
V) with Charles Esmon and colleagues in a 1995 issue of the journal Blood (Taylor
et al., 1995).
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cell signaling, and Majerus has continued to publish work in this
ﬁeld (Majerus et al., 1990; Ungewickell et al., 2005; Zou et al., 2012).
It seems plausible that Majerus simply lost interest in his factor Va
anticoagulant work as other signiﬁcant discoveries occupied his
attention. Given these hurdles, and since there was no clear clinical
relevance or other factor that may have shifted the ﬁnding to a
matter of concern, Majerus’ factor V anticoagulant work was not
integrated into the broader scientiﬁc framework (Latour, 2004,
2005).
On a related note, Majerus has a history of taking a very
methodical and patient approach to scientiﬁc investigation. Maje-
rus’ own words in his presidential address at the American Society
for Clinical Investigation annual meeting in 1982 on scientiﬁc
integrity are quite telling in this respect.
Progress in science is episodic and discontinuous. Thus, over the
long haul a creative and persistent investigator is certain to
produce new information. However, the pace of discovery de-
pends on vagarious factors. Suppose two equally talented in-
dividuals are working on hypotheses, one of which is correct,
the other incorrect. There is no a priori reason to conclude that
one hypothesis is more likely to be correct. In this case, the
person with the correct hypothesis will get “results,” the other
will fail. Thus, in the short run one person appears better than
the other, in the long run it will even out. We are in a marathon,
not a 100-yard dash!(Majerus, 1982)
In keeping with this view that successful short-term results did not
mark one as a “good” or “bad” investigator, perhaps Majerus
patiently carried out his work and resisted the urge to hype his own
results. Instead, it could be that Majerus expected the scientiﬁc
community would decide much later what his important contri-
butions had been, and that it was not his role to dictate to them
what was noteworthy or what had been overlooked. Thus, this new
anticoagulant role for factor V ﬁrst proposed in 1983 did not hold.
Latour conceptualized the idea of “science in the making”, in which
he claims “when things hold they start becoming true.” (Latour,
1987) (p4,12). While the circumstances surrounding the factor Va
anticoagulant work were not favorable for widespread scientiﬁc
acceptance and did not ultimately become “true,” the subsequent
proposal of a different factor V anticoagulant function would draw
much greater recognition and this 1994 proposal would ultimately
hold “true”.
5. Björn Dahlbäck and the second proposed anticoagulant
role for factor V
Björn Dahlbäck completed his PhD training under the guidance
of Dr. Johan Stenﬂo at Lund University in Sweden and his ﬁrst
biochemical study on coagulationwas published in 1978 (Dahlback,
2008a; Dahlback & Stenﬂo, 1978). During his thesis work, Dahlbäck
“managed to devise a puriﬁcation procedure for human factor V.”
(Dahlback, 1980, 2013). Dahlbäck used a combination of fraction-
ation, chromatography, and gel ﬁltration to purify factor V from
human plasma (Dahlback, 1980). After a post-doctoral fellowship at
the Scripps Research Institute in La Jolla, he returned to the clinical
chemistry department at Lund University. In 1986, Dahlbäck began
serving as a consultant to the coagulation unit of his hospital,
where he was “exposed to practical questions related to laboratory
investigation of thrombosis patients.”(Dahlback, 2008b) This
experience was an important ﬁrst step towards his future success.
In the fall of that year, one of the coagulation unit technicians, Ing-
Marie Persson, was analyzing a male patient’s blood sample to try
to determine the cause of thrombosis, and came across a curious
ﬁnding (Dahlback, 2003). Persson had conducted a functionalprotein C assay, in which protein C was puriﬁed from patient
plasma, “activated with the thrombin-thrombomodulin complex”,
and the ability of activated protein C to extend the clotting timewas
measured (Hickton, Felding, Ikeda, Martinsson, & Nilsson, 1986).
Since they knew at the time that activated protein C inactivated
factor Va and factor VIIIa, addition of activated protein C would be
expected to extend the time needed for coagulation. However,
depending on the assay conditions, the results of the assay were
either normal or abnormal, meaning that the APC either extended
the clotting time as expected or it did not extend the clotting
time (Dahlback, 2008b). Persson and Dahlbäck weren’t quite sure
what to make of the results, but as this line of investigationwas not
a top research priority in Dahlbäck’s lab, it languished without
much further progress. Dahlbäck “never expected it to become.
important.” He viewed it as “more or less just for fun.” (Dahlback,
2013). However, he recalls that “the poor APC response, the APC
resistance as we called it, in the patient’s plasma was always in the
back of my mind, nagging me as an unresolved problem.”
(Dahlback, 2003). Despite his underlying interest in the APC
resistance, the project was ofﬁcially suspended in 1990 when
Dahlbäck was a Greenberg visiting scholar at the Oklahoma Med-
ical Research Foundation in Oklahoma City.6
However, when Dahlbäck returned six months later, he held a
professorship at Lund University and he was appointed as head of
the laboratory section of the coagulation unit at Malmo, which
again allowed him easy access to patient samples. In the fall of
1990, he contacted the original patient’s doctor (Dr. Magnus
Carlsson) to get a new blood sample so he could return to work on
understanding why plasma from this male patient produced un-
clear results in the functional protein C assay. This time, it appears
that Dahlbäck was more focused on addressing this interesting
ﬁnding.
Dahlbäck and colleagues hypothesized that a patient’s resis-
tance to the anticoagulant effects of APC would lead to thrombosis,
so beginning in the summer of 1991 they developed a novel assay
that would allow them to measure this resistance. The assay was
straightforward: the investigators added normal APC to isolated
patient plasma, and elongation of clotting timewasmeasured using
the newly developed APTT assay (Dahlback, 2003, 2008b). Philip
Majerus would later describe this assay, that looks at the blood
clotting time in the presence and absence of APC, as a “simple yet
ingenious assay” tomeasure defects in APC activity (Majerus, 1994).
In normal circumstances, the addition of APC to plasma would
prolong the coagulation time because APC inactivated factor Va and
factor VIIIa. However, when this assay was used on plasma from
patients with a history of thrombosis, it detected an entirely new
patient segment, one with resistance to the anticoagulant effects of
APC (Majerus, 1994).
Under the supervision of Dahlbäck, Dr. Peter Svensson began
work in the clinical section of the coagulation unit at Lund Uni-
versity in September of 1992. He launched his research project by
going through old patient records to identify relevant patient
samples on which he could carry out this new assay (Dahlback,
2003). As described in a February 1993 Proceedings of the National
Academy of Sciences article, Dahlbäck and Svennson described a
proband (the initial patient) with a history of thrombosis and his
extended family (Dahlback, Carlsson, & Svensson,1993). Using their
assay, Dahlbäck and colleagues found evidence for resistance to
APC in 14 members of the extended family as well as two unrelated
smaller families (Dahlback, 2003). Dahlbäck and colleagues
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somal dominant mode of inheritance.
Excited by their discovery of a genetic basis for the APC resis-
tance, which they felt was the cause of the patient’s thrombosis, the
authors then proposed and tested a number of possible mecha-
nisms for the APC resistance. They considered every step in the
coagulation cascade to determine where the problemmight be and
proposed the following reasons for the APC resistance: an antibody
to protein C was blocking its activity, a protease directed against
protein C was degrading it, a deﬁciency in the anticoagulant protein
S, a mutation in the APC cleavage site of factor VIII, a mutation in
the APC cleavage site of factor V, a mutation in the procoagulant
vonWillebrand factor, or the existence of a novel protein C cofactor.
While many of these options were carefully ruled out (including
linkage analysis to rule out mutations in factor VIII and von Wil-
lebrand factor), it is important to note that the authors did not carry
out genetic analysis of factor V in these patients even though the
complete coding region of the factor V gene had been sequenced in
1987 (Jenny et al., 1987; Kane & Davie, 1986). The lack of known
genetic variants in the factor V gene and the fact that the intron
sequences had not yet been determined made it more challenging
for Dahlbäck to use a “PCR-based approach” to explore the possi-
bility of a mutation in factor V (Dahlback, 2003). Interestingly,
based on additional functional assays that were not deﬁnitive, the
authors concluded that it was not necessary to further explore the
possibility of a factor V mutation as the cause of APC resistance.
Instead, Dahlbäck and colleagues favored the possibility of a mu-
tation in a novel APC cofactor as the cause of thrombosis in the APC-
resistant individuals (Dahlback et al., 1993). At a time when very
few cases of thrombosis could be explained genetically, this paper
was enthusiastically received because it demonstrated a new risk
factor for thrombosis. Because of the clinical signiﬁcance of this
ﬁnding, this new APC cofactor quickly became a matter of concern
(Latour, 2004, 2005). Numerous research groups, including Dahl-
bäck’s, subsequently published reports demonstrating that APC
resistance could be detected in a signiﬁcant portion of patients with
thrombophilia (Koster et al., 1993; Legnani, Palareti, Biagi, &
Coccheri, 1994; Svensson & Dahlback, 1994) (Grifﬁn, Evatt,
Wideman, & Fernandez, 1993).
The plethora of reports of APC-resistant patient populations
provided opportunities for scientists to comment on Dahlbäck’s
proposal of a defective APC cofactor. Grifﬁn and colleagues
acknowledged that APC-resistant individuals might be missing a
functional APC cofactor as proposed by Dahlbäck, but they also
proposed the possibility that the APC-resistant patients possessed a
defective anticoagulant factor. Regardless of whether this factor
was an APC cofactor or a direct anticoagulant factor, the authors felt
that it was clearly involved in the protein C pathway (Grifﬁn et al.,
1993). Koster and colleagues acknowledged Dahlbäck’s hypothesis
that APC resistance was due to a defective APC cofactor, but they
emphasized that this proposal had not been formally demonstrated
and the cause of the APC resistance remained unknown (Koster
et al., 1993). In response, Dahlbäck’s group used a follow-up pa-
per to reinforce their previous assertion that APC-resistant in-
dividuals have a defect in an APC cofactor and that a defect in factor
V had been ruled out as the cause (Svensson & Dahlback, 1994).
They would recant their words shortly thereafter, as an editor’s
note at the end of this paper stated that after this paper’s accep-
tance, the authors found evidence that the APC cofactor was, in fact,
factor V.
After the clinical signiﬁcance of this “missing cofactor” was
established and this cofactor became a matter of concern, the work
initially describing factor V as a cofactor to activated protein C was
formally published in the February 1994 issue of the Proceedings of
the National Academy of Sciences (Dahlback & Hildebrand, 1994).Plasma from an APC-resistant patient was used to determine the
identity of the putative APC cofactor. In attempting to purify the
APC cofactor Dahlbäck noticed that the puriﬁcation scheme they
were using was just like the one he had used years earlier for the
puriﬁcation of factor V (Dahlback, 1980, 1994). Using chromatog-
raphy to purify the APC cofactor, the authors demonstrated that it
appeared to be factor V. To determine whether it was factor V or
factor Va that displayed APC cofactor activity, they cleaved factor V
with thrombin and showed that the APC cofactor activity was lost.
Dahlbäck’s group therefore concluded that factor V (and not factor
Va) was likely to contain the APC cofactor activity. Because the
authors had so forcefully ruled out factor V as the cause of APC
resistance in these patients based on functional assays (Dahlback
et al., 1993), they took extra effort to discuss the reasons why it
was such a challenge to identify factor V as the missing cofactor.
Why has the APC cofactor activity not been discovered previ-
ously? Factor Va is a major substrate for APC and easier to
handle andmore readily available than factor VIIIa. Most studies
aimed at the elucidation of the function of APC and its possible
cofactors have therefore used degradation of factor Va
(measured with factor V assays) as a means of monitoring APC
activity. This approach, which was successful for the identiﬁ-
cation of protein S as a cofactor for APC, is obviously inadequate
to identify factor V as an APC cofactor. The present identiﬁcation
of factor V as an APC cofactor was dependent of the availability
of plasma from an individual with inherited APC resistance.
(Dahlback & Hildebrand, 1994)
Thus, Dahlbäck and Hildebrand argued that it would have been
very difﬁcult to identify this additional property of factor V given
the “experimental system” that had been used at the time
(Rheinberger, 1997). Since factor Va, or the procoagulant form of
factor V, was a key component used in the assay to determine APC
function, it was nearly impossible to discover the novel cofactor
role for factor V using this assay.
In concluding their paper describing factor V as the missing APC
cofactor, Dahlbäck and colleagues argued: “We believe that factor V
is the ﬁrst coagulation protein demonstrated to express anticoag-
ulant properties as well to be (sic) the precursor to a procoagulant
cofactor, and our present results emphasize the importance of the
balance between pro-and anticoagulant properties of the coagu-
lation factors.”(Dahlback & Hildebrand, 1994) Strikingly, they make
no mention of Majerus’ 1983 work on the anticoagulant role of
factor Va as a cofactor in the activation of protein C to APC. How-
ever, in a 2013 interview, Dalback states that he “was quite aware.
that [factor Va] was reported. to be a cofactor [for the activation
of protein C],.but since this was related to the effect of activated
protein C, I, no, I don’t recall that I had even thought about that in
connection to what we had seen.”(Dahlback, 2013) Thus, Dahlbäck
stated that hewas interested in the function of protein C after it was
activated (APC), and therefore did not focus on the role of factor Va
in the actual activation of protein C.
Within three months of Dahlbäck and Hildebrand’s paper
demonstrating that factor V is a cofactor for APC, Rogier Bertina and
colleagues conﬁrmed the cofactor ﬁnding and described a genetic
defect, the factor V Leiden mutation, responsible for APC resistance
(Bertina et al., 1994). As described in the seminal Nature paper, the
factor V Leiden mutation is a single point mutation in the factor V
gene corresponding to a change at amino acid 506 in the factor V
protein. Using both functional tests and genetic analysis, the factor
V Leiden mutation was identiﬁed in individuals with resistance to
APC. Perhaps most compelling to clinical biochemists, the authors
provided evidence that the factor V Leiden mutation would cause
the corresponding factor Va Leiden protein to be resistant to
cleavage by APC (Bertina et al., 1994). While Bertina and colleagues
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article, their ﬁnding did later cast doubt on the factor V cofactor
role. In fact, many scientists felt that the inability of APC to inacti-
vate factor Va Leiden nicely and completely explained the increased
thrombosis risk.
Within a month of the Bertina factor V Leiden publication, Sun
and colleagues published a similar report, demonstrating that
factor Va was resistant to cleavage by APC in two APC-resistant
patients. The authors initially undertook this study to charac-
terize Dahlbäck’s proposed APC cofactor, called cofactor 2
(Dahlback et al., 1993). When Sun and colleagues were not able to
purify this putative cofactor, they decided to explorewhether factor
V or factor VIII were themselves somehow defective in these APC-
resistant patients. The investigators proceeded, through a series of
straightforward experiments, to demonstrate that factor Va is
resistant to APC cleavage in these APC-resistant patients. They also
made reference to their own unpublished results in which they
identiﬁed the same factor V Leiden mutation corresponding to
amino acid 506 in APC-resistant individuals. They claimed that
factor Va couldn’t be cleaved in the APC-resistant patients and
contrasted this with Dahlbäck’s view that APC-resistant patients
lacked an APC cofactor.
Hence, although Dahlbäck and Hildebrand’s report and our
studies coincide in the hypothesis that APC resistance is caused
by factor V abnormalities, these two reports differ signiﬁcantly
in the hypothesized molecular defects, with the former sug-
gesting that factor V but not Va is an APC cofactor and the latter
here proposing that the patients’ factor Va is literally and bio-
chemically APC resistant. . We speculate that molecular de-
fects causing APC-resistant factor Vawill provide an explanation
for most APC-resistant patients. However, the additional or
alternative possibility that factor V is an APC cofactor 2 cannot
be excluded and clearly merits direct biochemical and genetic
studies. (Sun, Evatt, & Grifﬁn, 1994)
Thus, the authors viewed the APC resistant phenotype as having
just one cause, and they felt that the lack of Va cleavage by APC was
more likely than a defective factor V cofactor. Jan Voorberg and
colleagues made a similar claim as well, stating that their data
provided evidence against a missing APC cofactor in APC resistant
individuals: “The data suggest that APC resistance is not due to a
deﬁciency of a cofactor of APC as has been proposed, but merely
reﬂects the inability of APC to inactivate the pro-coagulant factor
V.” (Voorberg et al., 1994). Even Dahlbäck seemed to view APC
resistance as being due to one of two possibilities: either “increased
resistance to APC of mutant factor Va itself and/or to loss of the
putative anticoagulant activity of factor V.” (Zoller & Dahlback,
1994). In fact, in an interview with Dahlbäck in 2013, he states
“So at the time I was convinced that it was a cofactor but I didn’t
believe that it was a defective cofactor that caused the APC resis-
tance but that this mutation was mainly though the degradation of
Va.” (Dahlback, 2013). Thus, many scientists at the time rejected
the possibility that the APC resistant phenomenonwas due to more
than one cause; scientists advocated for the simpler explanation in
which APC resistance was due to one cause.
Despite Dahlbäck’s continuous assertions that factor V serves as
a cofactor to the anticoagulant APC, the scientiﬁc community
remained unconvinced. In a commentary on the Voorberg and
Zoller articles in The Lancet, Tuddenham raises these questions
about the validity of factor V as an APC cofactor.
In February last year Dahlbäck and colleagues caused a sensa-
tion in blood coagulation circles by predicting a novel antico-
agulant cofactor in the protein C pathway. Deﬁciency of the new
factor, named activated protein C (APC) cofactor 2, was soonshown by several groups of workers in a high proportion of
patients with venous thromboembolism. The inference that a
cofactor to activated protein C was involved was based on the
ﬁnding of an abnormal coagulation assay in an index patient
that could be corrected by the addition of normal plasma.We
now need to consider the basis of the laboratory test in more
detail since the recent identiﬁcation of the putative cofactor
raises doubts about the interpretation of the original results..
The “new cofactor” has now been identiﬁed as “old” factor V.
Since APC cofactor 2 turns out to be factor V, we must conclude
that the plasma of patients with APC resistance contains factor V
molecules that are normal in procoagulant activity but
abnormal in terms of promoting their own destruction by acti-
vated protein C. This awkward and byzantine explanation is
probably superseded by the results published in this issue of The
Lancet and in the recent paper from Bertina et al. (Tuddenham,
1994)
As so succinctly shown by the last sentence of the above quote, the
identiﬁcation of the factor V Leiden mutation made it easier for
Tuddenham (and other scientists) to disregard Dahlbäck’s hy-
pothesis that factor V serves as a cofactor to APC. Instead, it was
perhaps more straightforward to think of the APC resistance as
being due to the inability of APC to cleave the mutant factor V
Leiden. Furthermore, Dahlbäck’s premature exclusion of factor V as
a candidate for the missing cofactor likely made some groups
question his credibility on thematter entirely, making it even easier
to disregard his cofactor hypothesis. Latour calls this a “dismissal
effect”, which can be “heightened by. the well-known blunder.”
(Latour & Woolgar, 1986) (p155).
Not giving up on the factor V anticoagulant cofactor hypothesis,
Shen and Dahlbäck published a report in the July 1994 issue of the
Journal of Biological Chemistry in which they tried “to in another
way show that factor V actually is a cofactor”(Dahlback, 2013) for
APC. In this publication, they showed that APC needs both protein S
and factor V as cofactors for efﬁcient degradation of factor VIIIa.
Dahlbäck stressed that factor V and not factor Va is the required
cofactor, and demonstrated this with a factor VIIIa activity assay
that he and Shen had developed. In describing the necessity for this
study, they state: “The recent ﬁnding that the majority of patients
with APC resistance have a mutation affecting an APC cleavage sites
(sic) in factor Va has cast doubt on our conclusion that factor V has a
function as a cofactor to APC.” (Shen & Dahlback, 1994). From the
experiments presented in this paper they concluded that factor V
and protein S work “synergistically” in the APC-mediated cleavage
of factor VIIIa (Shen & Dahlback, 1994). As discussed in a review
several years later, the publication of this particular paper was
pivotal in revitalizing the factor V APC cofactor idea.
In this respect it is important to recall the original observations
of Dahlbäck and co-workers who reported that the impaired
response of the activated partial thromboplastin time to APC-
resistant patients is corrected with normal plasma and with
puriﬁed factor V. On the basis of these observations, they
concluded that APC-resistant individuals lack a cofactor of APC
required for efﬁcient down-regulation of thrombin formation, a
hypothesis that fell in oblivion when it was shown that APC
resistancewas caused bymutation in factor V at an APC cleavage
site. Recent publication in which it was reported that factor V
stimulates inactivation of factor VIII(a) by APC may, however,
provide an explanation for the original observations of Dahlbäck
et al. (Rosing & Tans, 1997b)
From this point on, there was more acceptance of Dahlbäck’s factor
V anticoagulant cofactor hypothesis by biochemists with a clinical
focus. Once Shen and Dahlbäck demonstrated that factor V could
Fig. 4. The relative contribution of factors accounting for the APC-resistant phenotype
over time. The APC-resistant phenotype was initially viewed to be the result of a
missing factor V cofactor. With the discovery of the factor V Leiden mutation, the
inability to properly cleave factor Va was thought to be the cause of the APC-resistant
phenotype. Current data suggests that both factors contribute equally to the APC-
resistant phenotype.
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scientists were perhaps forced to rethink their previous rejection of
Dahlbäck’s factor V cofactor hypothesis and view APC resistance as
a result of both the inability of APC to properly cleave factor Va
Leiden and the inability of factor V Leiden to serve as a functional
cofactor for APC. Reﬂecting again on Latour’s concept of “science in
the making,” the second proposed anticoagulant role for factor V
was “becoming true” because was holding up over time (Latour,
1987) (p12). Furthermore, because of the clinical signiﬁcance of
this work, there was motivation for other researchers to replicate
and extend this work.
The anticoagulant function of factor V was reinforced in a New
England Journal of Medicine editorial, in which Katherine Hajjar
depicted factor V as a cofactor (along with protein S) in the APC-
mediated cleavage of factor VIIIa (Hajjar, 1994). Interestingly,
Hajjar also presented factor Va as a cofactor (along with thrombin
and thrombomodulin) in the generation of APC from protein C and
this functionwas depicted in the same ﬁgure. This renewed interest
in Majerus’ work may have been sparked by his own previous
comments regarding the factor V Leiden work in which he stated:
“The anticoagulant actions of V and Va have been subject to much
less attention. At least two such functions have been proposed.
Thus factor Va but not V stimulates the activation of protein C by
thrombin, and factor V but not Va is a cofactor for the action of APC
according to Dahlbäck.” (Majerus, 1994).
Also in 1994, Majerus’ anticoagulant factor Va work was rein-
forced in a biochemical paper about APC-mediated inactivation of
factor V and factor Va, in which the authors discussed the factor Va
anticoagulant properties: “The known anticoagulant properties of
human factor Va are: 1) the intrinsic property of the membrane-
bound cofactor to be inactivated, as a substrate, by APC by pro-
teolysis at Arg506 and Arg306 of the heavy chain; and 2) the
ability of the light chain of factor Va to act as a cofactor for the
thrombin-dependent activation of protein C.” (Kalafatis, Rand, &
Mann, 1994). However, many groups did not mention the orig-
inal anticoagulant role for factor Va in papers published during
this period, and the interest in Majerus’ work on the subject was
short-lived.
Even Dahlbäck, who potentially had the most to gain from citing
the historical precedent for a procoagulant factor V/Va protein
acting as an anticoagulant, did not often mention Majerus’ work. In
a 1995 review by Dahlbäck, he begins with an overview of protein C
activation andmentions the role of thrombomodulin (but not factor
Va) as a cofactor in the thrombin-mediated activation of protein C
to APC. Only later on in the review did he point out that “Another
anticoagulant function of factor Va of unknown physiologic sig-
niﬁcance was proposed more than 10 years agowhen factor Va, but
not factor V, was found to stimulate activation of protein C by
thrombin and by the thrombin-TM complex.” (Dahlback, 1995). In
responding to why he thought Majerus’ factor V anticoagulant
work had not been followed up, Dahlbäck states, “I think that it
could be that people really tried and they couldn’t see [the expected
results] and they were discouraged. If people can’t repeat, if several
people can’t follow up, I think then they [the results] are not so
accepted after some time.” (Dahlback, 2013). In fact, in the 1990s
one of Dahlbäck’s students tried to see if factor Va exerted a stim-
ulating effect on protein C activation and they “couldn’t actually see
any.” (Dahlback, 2013). However, Dahlbäck states “I don’t
remember if we tried exactly the setup that they had but we tried
some along those lines.” (Dahlback, 2013). Given Majerus’ track
record of detailed and thorough scientiﬁc work, it is possible that
his results were not repeated by independent laboratories due to a
lack of motivating factors (such as clinical relevance) for others to
devote the time and resources to work out the technical details to
successfully carry out the assay. It is even possible that important“tacit knowledge” may have been omitted from the original sci-
entiﬁc publication (Giles, 2006; Polanyi, 1966). Although reference
to Majerus’ anticoagulant factor Va work was short lived, Dahl-
bäck’s anticoagulant workwould continue to gain acceptance in the
relevant scientiﬁc community. Dahlbäck’s anticoagulant factor V
work was holding up and becoming increasingly “true.” (Latour,
1987) (p12).6. Further development of the cofactor hypothesis
The long-term acceptance of Dahlbäck’s factor V cofactor hy-
pothesis was most vulnerable shortly after the factor V Leiden
mutation was discovered by Bertina and colleagues (Fig. 4). The
factor V Leiden ﬁnding gave the scientiﬁc community a simple
and concrete explanation for increased risk of thrombosis in
these patients: APC couldn’t cleave the procoagulant factor
Va when it possessed this mutation. Furthermore, the factor V
Leiden discovery came in the mid-1990s, a time during which
scientists had great hopes for the role that genetic knowledge
would play in medical treatment strategies (Guyer & Collins,
1993; Ropers, 2007). Thus, the allure of this explanation over-
shadowed other possible interpretations of what was going on,
and Dahlbäck alone seemed to think it insufﬁcient, perhaps in
part because he had the most to lose by the diminishing interest
in his factor V cofactor hypothesis. However, because Dahlbäck
persisted in promoting his cofactor hypothesis both in written
form and through experimentation, biochemists were forced to
consider his point of view.
Indeed, more detailed studies of the APC-mediated cleavage of
factor Va cast doubt on the view that the factor V Leiden mutation
made patients resistant to APC simply because factor Va Leiden
couldn’t be cleaved. Scientists ﬁrst thought that factor Va Leiden
wouldn’t be inactivated by APC because they believed that factor Va
needed to be cleaved at position 506 to be inactivated (Rosing &
Tans, 1997a). However, cleavage of factor Va at 506 was not sufﬁ-
cient to completely inactivate factor Va; factor Va cleaved at posi-
tion 506 could still function in the activation of prothrombin.
Cleavage at position 306, which occurred more slowly compared to
the 506 cleavage, is what completely inactivated factor Va (Nicolaes
et al., 1995). Therefore, these studies showed that both factor V and
factor V Leiden could actually be inactivated by APC, but factor V
Leiden was inactivated more slowly. Thus, the straightforward
explanation proposed in response to Bertina’s factor V Leiden dis-
covery no longer looked so robust.
8 It was technically challenging to test the ability of factor V to play a role in its
own cleavage.
9 Ernst Hook and Lawrence Stern have both argued that discoveries are less likely
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was associated with increased thrombosis risk because factor V
Leiden wasn’t cleaved by APC began to be questioned. As a result,
the importance of factor V as a cofactor for APC function was more
seriously considered. In 1996, Varadi and colleagues generated new
support for the role of factor V as a cofactor in APC function by
demonstrating that factor V Leiden does not function as well as
normal factor V as a cofactor for APC cleavage of factor VIIIa (Varadi
et al., 1996). Subsequent work would begin to clarify just how
important this role was.
In 2004, Castoldi and colleagues were interested in how factor V
Leiden (as well as other factor V mutations) might in theory cause
APC resistance either by (1) reduced factor V APC cofactor activity
or (2) reduced ability of APC to cleave factor Va. They stressed that
scientists hadn’t formally looked at the relative contribution of
these two factors, but that it had been assumed that the reduced
ability of APC to cleave factor Va was the more important factor in
thrombosis risk. Castoldi presented data demonstrating that factor
V Leiden does not have APC cofactor activity and that it actually
may somewhat inhibit APC activity. He and his colleagues then
demonstrated that APC resistance is due to approximately equal
contribution of the reduced cofactor activity (as measured by APC-
mediated cleavage of factor VIIIa) and the reduced ability of Va to be
cleaved (Castoldi et al., 2004). In a commentary that followed,
Dahlbäck stressed the importance of the Castoldi work in that they
had determined the relative contributions of factor V cofactor ac-
tivity vs. APC-mediated cleavage of Va in causing APC resistance,
and demonstrated that the cofactor activity was much more
important than previously recognized (Dahlback, 2004). Given that
both the factor V cofactor activity and the factor Va cleavage site
alteration played a role in APC resistance, no “conversion” event
was required to accept the cofactor hypothesis.7 Thus, the 2004
Castoldi study allowed for consensus to be achieved in a way that
did not require either those that supported the cofactor hypothesis
or those that supported the cleavage hypothesis to abandon their
original views. Instead, the two competing views became part of a
larger understanding of the mechanism behind APC resistance.
Further blows to the view that the inability to cleave at the
factor V Leiden mutation site was the dominant mechanism of APC
resistance continued to come as more patient samples were
analyzed. Two other mutations in factor V, termed FVHongKong
and FVCambridge, were identiﬁed and each was predicted to
contain a single amino acid change at position 306 of the factor V
protein, corresponding to an APC cleavage site (Chan, Lee, Kwong,
Lam, & Liang, 1998; Williamson, Brown, Luddington, Baglin, &
Baglin, 1998). Unlike the factor V Leiden mutation, however, these
mutations were not associated with signiﬁcant thrombosis risk,
and both versions were shown to serve as relatively functional APC
cofactors (Norstrom, Thorelli, & Dahlback, 2002). In contrast,
another mutation, FVLiverpool, was shown to increase thrombosis
risk and, correspondingly, the APC cofactor activity for this mutant
had been lost (Dahlback, 2004). Thus, it appeared that the ability to
be cleaved by APC was not quite as deﬁnite a marker for throm-
bosis, but the ability to act as a cofactor was.
Subsequently, many scientists viewed factor V Leiden as being a
risk factor for thrombosis because of two factors: (1) reduced ability
of APC to cleave factor Va Leiden; and (2) reduced ability of factor V
Leiden to serve as a cofactor for APC-mediated cleavage of factor
VIIIa (Brugge et al., 2005; Castoldi & Rosing, 2004; Rosendorff &
Dorfman, 2007). Thus, Dahlbäck’s cofactor hypothesis, in which7 As Kingsland illustrates in the history of the acceptance of Mendelism, “the
crucial mental event was the perception of the compatibility between ideas that
had previously seemed fundamentally different.” (Kingsland, 2007).factor V served an anticoagulant role as a cofactor in the function of
APC-mediated cleavage of factor VIIIa, was accepted. Due in part to
technical reasons, scientists had focused on the factor V cofactor
ability in the APC-mediated cleavage of factor VIIIa but not factor
Va.8 Yet in 2010, Cramer and colleagues demonstrated that factor V
is a cofactor in the APC-mediated inactivation of factor Va as
well (Cramer, Grifﬁn, & Gale, 2010). Thus, in addition to its pro-
coagulant role, factor V had been shown to be an anticoagulant
cofactor in the APC-mediated inactivation of both factor Va and
factor VIIIa.7. Conclusion
Even though Dahlbäck’s hypothesis of factor V serving as an APC
cofactor was actually more resisted by his peers than Majerus’
hypothesis about factor Va had ever been, a number of factors
differentiated the two discoveries and therefore may have played
key roles in the transformation of Dahlbäck’s discovery into a
matter of concern (Latour, 2004, 2005). I argue that the ﬁrst and
most signiﬁcant factor helping Dahlbäck’s factor V anticoagulant
hypothesis was that, unlike Majerus’ discovery, the basis of Dahl-
bäck’s work and others was the APC-resistant patient population.
Given that APC-resistant patients represented a signiﬁcant pro-
portion of patients with thrombophilia, scientists and clinicians
were particularly interested in understanding the molecular
mechanisms by which APC-resistance increased the risk of
thrombosis. This concept is reinforced by Latour’s argument
regarding the impact of scientiﬁc publications, when he states that,
“We are left, therefore, with the somewhat tautological speculation
that items which yield a high return are those with a high chance of
addressing issues of concern outside the laboratory.” (Latour &
Woolgar, 1986) (page 74). In the case of the factor V anticoagulant
work, the “issues of concern” are the patients with thrombophilia.
Consistent with this idea is Latour’s observation that the discovery
of releasing factor received a great deal of scientiﬁc attention
because of its importance in our understanding of sterility and the
potential implications of this discovery on the development of birth
control methods (Latour & Woolgar, 1986) (p214e215). Similarly,
Jones notes, “Plaque rupture became relevant in the setting of new
therapeutic interventions that promised to prevent or mitigate the
effects of a heart attack.” (Jones, 2013) (p79). Thus, the existence of
the APC resistant patient population was a key factor in the
acceptance of Dahlbäck’s factor V work because the patient popu-
lation made the work relevant, and therefore a matter of concern
(D. S. Jones, 2013) (p236) (Latour, 2004, 2005).
The second factor contributing to the acceptance of Dahlbäck’s
hypothesis was Dahlbäck’s own persistence in the promotion of his
ideas.9 As I’ve shown, despite several prominent articles dismissing
his hypothesis of factor V acting as a cofactor, Dahlbäck continued
to assert his hypothesis as valid, and continued to carry out ex-
periments to support his claim. In fact, it is possible that the
dismissal of his factor V cofactor hypothesis provided Dahlbäck an
opportunity to strengthen the evidence in favor of his claim. Shapin
states, “The ideal says that scientists should not be attached to their
theories, but the reality says that they are” (Shapin, 2008) (p51).to be accepted if they are not noticed by other scientists, as can happen if a dis-
covery is published in an obscure place, or, as Gillies argues in the case of Sem-
melweis, if the scientist doesn’t promote his ideas. In Gillies’ words, “Altogether
Semmelweis was not very good at promoting his own views.” Dahlbäck’s promo-
tion of his ideas may have led to his discovery being noticed by more scientists
(Gillies, 2005; Hook, 2002a; Stern, 2002).
M.L. LaBonte / Studies in History and Philosophy of Biological and Biomedical Sciences 47 (2014) 23e3432This is a clear illustration of a scientist being attached to a theory.
However, if Dahlbäck hadn’t been attached to his anticoagulant
factor V hypothesis, other scientists may not have replicated the
work and the current understanding of factor V would likely be
different than it is today. In other words, Dahlbäck’s factor V anti-
coagulant role may not have become “true.” (Latour, 1987) (p12).
While there are certainly downsides to such attachment to the-
ories, unpopular hypotheses are more likely to be accepted if this
type of attachment exists. Majerus’ stated approach quoted earlier
in this paper, in which he advocated the long view, is in contrast to
Dahlbäck’s approach to his cofactor hypothesis. Majerus’ advocacy
of a slow and steady approach to science may have contributed to
the lack of acceptance of his anticoagulant proposal. Furthermore,
Majerus’work took a different direction shortly after his 1983 factor
V discovery. “Scientists. cannot study everything they observe”
(Jones, 2013), and it is possible that Majerus did not continue to
follow up his factor V work because he was so successful in his
other areas of research.
Another important factor was that Dahlbäck’s anticoagulant
work was repeated and reinforced by other laboratories, whereas
Majerus’ work was not. As Dahlbäck recalls,
.Other labs tried and reported also the effect that, of course,
makes it more acceptable that other labs actually can see this
effect. So, I think this work done by Jan Rosing’s group in
Maastricht was very important to get the concept accepted also.
Especially, I think this work where they claimed that it was
around 60% of the effect, of the anticoagulant effect in plasma,
could be attributed to the anticoagulant function. I think that
had a major impact on getting also the concept accepted. I think
without that study it probably would not have been so well
accepted as it is now. So I think it helps a lot if other labs can
conﬁrm or even add more new aspects on such a topic.(Dahl-
back, 2013)
Consistent with this view, Latour argues, “an important factor in the
acceptance of a statement was the recognition by others of another
statement which was similar. The combination of two or more
apparently similar statements concretised the existence of some
external object or objective condition of which the statements were
taken to be indicators. Sources of ‘subjectivity’ thus disappeared in
the face of more than one statement, and the initial statement
could be taken at face value and without qualiﬁcation.” (Latour &
Woolgar, 1986) (page 83e84). Although the scientiﬁc community
initially refuted Dahlbäck’s work, others eventually reinforced his
ﬁndings. This concept of reinforcement is also echoed by Rhein-
berger when he states, “We may say that unprecedented events,
through recurrence, lead to conjunctures.” (Rheinberger, 1997)
(p135). Dahlbäck’s work was replicated and reinforced in large part
because of the clinical signiﬁcance of the APC resistant patient
population and his continued persistence may have created the
momentum needed for his work to be complimented and his hy-
pothesis to be accepted.
The inﬂuence of the scientists’ background is an additional
factor that may play a role in determining whether others accept a
claim (Gillies, 2005).10 However, the cases described in this paper
provided evidence that a scientist’s favorable reputation may be
necessary but not sufﬁcient for the acceptance of an idea. In dis-
cussing JamesWatson’s acceptance of Jerry Donohue’s advice not to10 Ignaz Semmelwies suggested that puerperal fever was caused by doctors
inadvertently transferring cadaverous material to women during childbirth. Ac-
cording to Donald Gillies, Semmelweis’ proposal that doctors use antiseptic treat-
ment before contacting patients was not accepted in part because of his rank and
nationality (Gillies, 2005).use the “enol form for picturing the bases. Watson chose to
believe Donohue rather than the general opinion expressed in the
textbooks for a variety of reasons, not least of which was evaluation
of Donohue’s career up to that date.. individual’s careers consti-
tute an important resource for evaluation of their claims.” (Latour &
Woolgar, 1986) (p171). Consistent with this idea is Dahlbäck’s own
view that his reputation was an important factor in the acceptance
of his anticoagulant factor V cofactor hypothesis. As he recently
recalled, “it was still considered groundbreaking, the importance of
this APC resistance, and if somebody else had proposed factor V
anticoagulant role maybe it would not have been so quickly
accepted.” (Dahlback, 2013). However, the cases reviewed in this
paper suggest that a strong reputation may be an important factor
in the acceptance of an idea, but it is not sufﬁcient to lead to the
acceptance of a novel and unexpected ﬁnding. At the time of the
publication of his 1983 factor V anticoagulant paper, Majerus had
93 prior publications, 91.4% of which were either ﬁrst or last au-
thorships. When Dahlbäck’s 1994 factor V anticoagulant paper was
published, he had 79 prior publications and 63.3% were ﬁrst or last
author publications. Both scientists were full professors at the time
of their respective factor V anticoagulant publications. Therefore, I
would argue that Majerus’ reputation at the time of his 1983
anticoagulant claimwas just as impressive as Dahlbäck’s reputation
at the time of his 1994 anticoagulant claim, yet only one of the two
proposed anticoagulant roles was incorporated in the scientiﬁc
framework and viewed as “true” (Latour, 1987) (p12).
The ease with which a new ﬁnding can be ﬁt into the existing
framework of scientiﬁc knowledge has been proposed, in various
formulations, as a factor that determines whether the relevant
scientiﬁc community will accept a ﬁnding. However, the two factor
V cases presented in this paper demonstrate that difﬁculty in ﬁtting
a new ﬁnding into the existing framework does not necessarily
preclude that ﬁnding from being accepted by the relevant scientiﬁc
community. The two anticoagulant factor V proposals presented by
Majerus and Dahlbäck went completely against the strictly pro-
coagulant role for factor V that was accepted at the time of each of
the discoveries, yet Dahlbäck’s discovery was accepted by clinical
biochemists and Majerus’s discovery was not. In 1972, Gunther
Stent put forth the idea that discoveries will not be accepted if they
are premature. In his words, “A discovery is premature if its im-
plications cannot be connected by a series of simple logical steps to
canonical, or generally accepted, knowledge.” (Stent, 1972).11 While
the legitimacy of this notion of prematurity has been contested,12
many have argued that there is value in examining how easily a
discovery can be integrated into the existing scientiﬁc framework
when considering reasons why some discoveries are overlooked.
Along these lines, Martin Jones has proposed focusing on the
“unconnectability condition” and Elihu Gerson suggests that we
“speak instead of an ‘unconnected’ discovery.” (Gerson, 2002;
Jones, 2002). Furthermore, Augistine Brannigan has suggested
that discoveries aremore likely to be accepted if they are consistent
with “expectation states” such that the discovery is anticipated
(Brannigan, 1981) (p72). Even though Dahlbäck’s anticoagulant
factor V discovery was “unconnected” in its original formulation, it
is possible that the clinical relevance and Dahlbäck’s persistence in
promoting this new ﬁnding provided incentive for scientists to
conduct experiments that led to “connections” between the11 Stent’s strict deﬁnition of prematurity applies to discoveries that are overlooked
initially but then later accepted. For discoveries that are overlooked at the present
time, Stent proposes the term “here-and-now prematurity.”
12 Nathaniel Comfort stresses that the “assumption of prematurity renders un-
necessary, or at least nonobvious, the contextualization that makes good history.”
(Comfort, 2002).
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there when the work was ﬁrst published in 1994.
As an indication of the acceptance of the second proposed
anticoagulant role for factor V, a 2012 review was dedicated to the
anticoagulant functions of factor V and focused entirely on the
mechanism of action of factor V as a cofactor in the APC-mediated
cleavage of factor Va and factor VIIIa (Cramer & Gale, 2012). In this
same review, there was not a single reference to Majerus’ work on
the anticoagulant role of factor Va as a cofactor in creating activated
protein C. Thus, signiﬁcant clinical interest in the APC-resistant
patient population and Dahlbäck’s tireless promotion of his
cofactor hypothesis resulted in the replication of Dahlbäck’s factor
V anticoagulant work. Once other labs were able to replicate and
extend Dahlbäck’s ﬁndings, widespread acceptance of the second
proposed anticoagulant role for factor V occurred. Futhermore,
Majerus’ strong reputation at the time of his discovery was not
enough to result in the acceptance of his anticoagulant factor V
proposal, and the initial “unconnected” nature of Dahlbäck’s anti-
coagulant factor V ﬁnding did not prohibit its eventual acceptance.
In future studies, it will be interesting to examine different cases to
determine howwell these three factors (relevance, persistence, and
replication) hold up when applied to other reports of novelty, or
whether a certain level of support, regardless of speciﬁc factors,
must be reached before a discovery will be accepted by the relevant
scientiﬁc community.
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